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ABSTRACT
Objectives: Eosinophilic oesophagitis (EO) shows
eosinophilic inﬁltration of the mucosa and can present
with symptoms indistinguishable from
gastrooesophageal reﬂux disease (GORD). The authors
describe the clinical, endoscopic and histopathological
features of all cases of histological EO presenting
during 2007e2008 with a 2-year follow-up. The
incidence of paediatric EO and the features of
a subgroup with features of both GORD and EO
(‘overlap’ syndrome (OS)) are described.
Design: Biopsies with an average of 15 eosinophils/
high-power ﬁeld (HPF) were reviewed in the cohort. OS
was suggested when there was coexistence of clinical
and histological features of EO and GORD (abnormal
pH study), which improved with proton pump
inhibitors.
Setting: Tertiary care.
Participants: All cases with $15 eosinophils/HPF
entered the study.
Primary outcome measures: Patients with EO had
an average of 15 eosinophils/HPF.
Secondary outcome measures: Other histological
features of EO included microabscesses, dilated
intercellular spaces, basal cell hyperplasia, papillary
elongation, etc.
Results: 24 cases of EO were identiﬁed, 13 men and
11 women. The incidence of paediatric oesophageal
eosinophilia in the region was 9/100000 children. 11
of the 24 patients (46%) presented with some form of
allergy, six with poor feeding/food aversion, ﬁve with
dysphagia and four with vomiting. After follow-up,
56.5% were conﬁrmed to have EO, 30.5% responded
to treatment for GORD and were categorised as OS,
9% developed eosinophilic gastroenteritis and 4% did
not have further upper gastrointestinal symptoms.
Conclusions: Accurate diagnosis of EO, especially the
differentiation from GORD, requires appropriate
clinicopathological correlation. A signiﬁcant proportion
of patients with eosinophilia in the mucosa also have
GORD (OS). These patients improve after treating the
underlying GORD. The study was registered as
a Service Evaluation with the Trust (number SE74).
INTRODUCTION
Gastrooesophageal reﬂux (GOR) is a condi-
tion in which an abnormal reﬂux of gastric
contents occurs into the oesophagus. It can
be asymptomatic, but when it causes symp-
toms, it is called gastrooesophageal reﬂux
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ARTICLE SUMMARY
Article focus
- To estimate the incidence of oesophageal
eosinophilia in the paediatric population of our
region.
- To describe the clinical presentation and the
endoscopic appearances at presentation.
- To appraise the natural history after 2-year
follow-up and to recognise the clinical features
of those cases that showed an overlap with
gastrooesophageal reﬂux.
Key messages
- During follow-up, 56.5% cases had eosinophilic
oesophagitis conﬁrmed, 9% improved with
proton pump inhibitor treatment (overlap
syndrome), 9% developed eosinophilic gastro-
enteritis and in 4% symptoms did not recur.
- In 3 of the 13 patients with abnormal pH study
(23%), the failure of proton pump inhibitor
treatment and the improvement with oral
steroids and/or diet modiﬁcation, placed them
in the category of eosinophilic oesophagitis.
- The incidence of eosinophilia in the oesophagus
in our region is 9/100000 children, while that
of eosinophilic oesophagitis is 4.5/100000
children.
Strengths and limitations of this study
- Deﬁnes the epidemiological features of oesopha-
geal eosinophilia in the paediatric population in
our region.
- Highlights the importance of keeping longitudinal
data on these patients.
- The retrospective nature prevented a uniform
clinical approach.
- The small number of patients that underwent full
evaluation for gastrooesophageal reﬂux disease
weakens the conclusions on overlap syndrome.
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Open Access Researchdisease (GORD). Histologically, the mucosa of the distal
oesophagus shows basal cell hyperplasia, papillary elon-
gation and intraepithelial eosinophils (usually <15/
high-power ﬁeld (HPF)).
1
Since Winter et al
2 suggested that the presence of
intraepithelial eosinophils in the distal oesophageal
mucosa is a highly speciﬁc diagnostic criterion for
GORD, several reports during the following years have
identiﬁed adult and paediatric patients who failed to
respond to acid blockade treatment and showed high
numbers of intraepithelial eosinophils in the oesopha-
geal mucosa. These patients presented with a variety of
symptoms including poor weight gain, food refusal,
dysphagia, vomiting and allergic symptoms.
3e5
After being initially reported in 1978 in an adult
patient with severe achalasia,
6 Attwood et al
7 were the
ﬁrst to identify eosinophilic oesophagitis (EO) as a newly
recognised clinicopathological entity in young adults,
predominantly males, presenting with dysphagia in the
presence of a normal barium swallow, normal endoscopy
and normal oesophageal acid exposure on 24 h pH
monitoring.
EO is an emerging clinicopathologic condition char-
acterised by severe eosinophilia restricted to the
oesophagus in patients in whom GORD has been
excluded by normal pH monitoring and failure to
respond to high-dose proton pump inhibitor (PPI)
therapy.
8e10 It is a chronic interleukin 5-driven inﬂam-
matory disorder in which the aetiology seems to be
linked to a combination of allergic and immunologic
responses.
11 12 The immune responses in EO are char-
acterised by enhanced production of T helper cell 2
cytokines as a result of the interplay between genetic
predisposition, environmental exposure, allergic sensi-
tisation, eosinophils, mast cells and cytokines.
10 12 13
The last decade witnessed a rise in the diagnosis of this
entity in both adults and children.
14e16 More recently, new
clinical, endoscopic, immunologic and histological
features have emerged alongside pioneer microarray
genetic studies aimed to provide a more thorough
understanding of the pathophysiological mechanisms
involved in the development of EO.
10 17 18 The problem
faced by paediatric pathologists and clinicians when ﬁrst
confronted with an oesophageal biopsy showing intra-
epithelial eosinophilia is the uncertainty about what the
underlying cause could be: EO, GOR, allergy or eosino-
philic gastroenteritis. These lead us to seek a correlation
between the histological features at a ﬁrst biopsy with
oesophageal eosinophilia (with an average of at least
15 eosinophils/HPF) presenting at our institution
between 2007 and 2008 and the ﬁnal clinical diagnosis
after a 2e4-year follow-up. We also sought to deﬁne the
incidence of oesophageal eosinophilia in the paediatric
population of South Yorkshire, a north of England county.
MATERIALS AND METHODS
All oesophageal biopsies with an average of at least 15
eosinophils/HPF received in our department between 1
January 2007 and 31 December 2008 were retrieved from
our ﬁles and retrospectively reviewed by one of the
authors as part of a service evaluation project (MCC).
The eosinophil count was performed on the HPF with
highest concentration of intraepithelial eosinophils
(ocular magniﬁcation of 103, lens magniﬁcation of
403, microscopic ﬁeld: 0.196 mm
2 Nikon microscope).
Histologically, EO was deﬁned by the presence of at
least 15 eosinophils/HPF in the oesophageal mucosa in
the absence of involvement of other parts of the
gastrointestinal tract (eosinophil counts in the rest of the
gastrointestinal tract were within the normal ranges
published by DeBrosse et al
19). Other histological
features sought in our cohort included microabscesses
(groups containing more than four eosinophils), dilated
intercellular spaces (DIS), basal cell hyperplasia ($30%
of the mucosal thickness), papillary elongation ($70%
of the mucosal thickness), increased number of
‘squiggle cells’ (>6/HPF) and epithelial cell vacuolation
(presence of clear vacuoles in the cytoplasm). If any of
the biopsies included the lamina propria, the presence
or absence of ﬁbrosis was assessed.
The clinical notes were reviewed to obtain the demo-
graphic, clinical and endoscopic features of the cohort at
presentation and after a 2-year follow-up. All endoscopy
procedures were performed using Olympus XP240 or
XP260 scopes. ‘Overlap’ syndrome was deﬁned by the
presence of clinical and histological features of EO
together with GORD (abnormal pH study).
Our institution is the only specialist paediatric gastro-
enterology centre in the region. Therefore, the inci-
dence of oesophageal eosinophilia in our region was
calculated based on the population of children in our
catchment area (data obtained from the United King-
dom’s Ofﬁce of National Statisticsd2009 ﬁgures).
20
The study was registered as a Service Evaluation with
the Trust (number SE74).
RESULTS
Twenty-four cases fulﬁlled the criteria for the histological
diagnosis of EO (three other cases were excluded as the
patients were diagnosed as having eosinophilic gastro-
enteritis at presentation).
The demographic, clinical and endoscopic character-
istics of our cases are shown in consecutive order in
tables 1 and 2.
There were 13 men and 11 women. The average age
was 6 years (range: 6 months to 15 years). Six patients
presented with poor feeding/food aversion, ﬁve with
dysphagia and four with vomiting. Clinical and labora-
tory tests performed either before or after the index
biopsy revealed that 11 of the 24 (46%) children had
some form of allergy: six patients had either eczema,
asthma or both (cases 1, 2, 9, 11, 15 and 18) and four
cases improved with dairy-free diet in keeping with cow
milk protein allergy (cases 6, 14, 17 and 19). In another
patient (case 5), although did not have clinical or
histological features of coeliac disease, the symptoms
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(91%) had a trial of PPI, either before or after the biopsy
results became available, without relief of their symp-
toms. A pH study was performed in 67% of our patients
(16 of the 24). In 7 of the 24 (29%) children (cases 4, 5,
8, 9, 10, 12 and 18), EO was associated with GORD,
fulﬁlling the criteria for the so-called overlap syndrome
(OS).
The endoscopic ﬁndings were described as: normal in
nine cases (38%), furrowing or trachealisation in 10 cases
(42%), Candida infection (white speckles) was suspected
in two cases (8%), erythema in keeping with oesophagitis
was queried in two cases (8%) and no description was
recorded in one case (4%) (see ﬁgure 1A).
The histological features are shown in table 3 and
ﬁgure 1BeD.
A total of 36 oesophageal biopsies were performed in
the 24 patients of the study, although only 35 of the 36
biopsies fulﬁlled the criteria of EO (this patient had
another simultaneous biopsy with EO). The biopsy site
was labelled as proximal in 10, middle in two and distal
in 13. No site was recorded in 11 specimens.
The average number of eosinophils in the 35 biopsies
from the 24 cases of the study was 32 (range 4e57)/HPF.
When this ﬁgure was analysed per biopsy site, the
corresponding average number and range of eosino-
phils/HPF was 24.5 (range 4e55)/HPF in the proximal
biopsies, 37.5 (range 22e55)/HPF in the middle biop-
sies, 38 (range 20e57)/HPF in the distal biopsies and 32
(range 16e45)/HPF in the unknown site samples.
Other features seen in EO were various degrees of
DIS, basal cell hyperplasia, papillary elongation and
Table 1 Demographic features, clinical history and endoscopic characteristics of the cohort children with oesophageal
eosinophilia on histology
Case Age Sex History Endoscopy
Clinical Dx pre-biopsy
result
1 23 m M Allergy, eczema, asthma,
feeding problems
Corrugated, furrowing,
trachealisation
EO
2 44 m M Dysphagia, intractable asthma Corrugated, furrowing EO
3 35 m F Reﬂux, food aversion Furrowing, ridging GORD
4 51 m F Failure to thrive, feeding problems,
developmental delay, epilepsy
Normal GORD
5 9 y F Poor weight gain, epigastric pain Normal GORD
6 19 m M No weight gain, poor appetite Normal ?GORD or non-ulcer
dyspepsia
7 39 m F Feeding problems, RusselleSilver
syndrome, food aversion
White speckles, ?
Candida oesophagitis
?GORD
8 15 y M Epigastric pain Severe oesophagitis ?GORD
9 6 m F Vomiting and mucosy diarrhoea,
asthma
No information available GORD
10 15 y M Dysphagia, GORD Normal ?GORD
11 23 m M Allergy, eczema, asthma, feeding
problems
Furrowing, trachealisation ?EO
12 15 m F ?GORD Normal ?GORD
13 13 y M Heartburn, difﬁculty swallowing
solids/liquids, family history of
peptic ulcer
Furrowing ?GORD
14 16 m F ?Cow milk protein intolerance Normal ?CMPA
15 12 y M Asthma, eczema, food bolus
obstruction
Furrowing Achalasia of
the cardia. ?EO
16 11 y M Food bolus obstruction Normal, pre-pyloric ulcer Gastritis
17 12 m F ?CMPA ?Candida oesophagitis ?CMPA
18 14 y F Asthma, eczema Furrowing ?EO
19 6 m M Failure to thrive, diarrhoea.
?protein-loosing enteropathy
Normal Likely CMPA
20 42 m F Abdominal pain, ?coeliac disease,
low IgA, poor weight gain
Normal Iron deﬁciency aneamia,
?coeliac disease
21 14 y M Diarrhoea Furrowing ?EO
22 10 y F Heartburn, reﬂux, vomiting Trachealisation ?GORD
23 16 m M Vomiting Oesophagitis ?GORD
24 11 m M Vomiting, failure to thrive,
medulloblastoma in remission
Corrugated and furrowed
oesophagus, trachealisation
?EO, ?GORD
CMPA, cow milk protein allergy; Dx, diagnosis; EO, eosinophilic oesophagitis; F, female; GORD, gastrooesophageal reﬂux disease; m, months;
M, male; y, year?: suspected clinical diagnosis.
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superﬁcial mucosa were identiﬁed in four patients (cases
2, 9, 10 and 17). An interesting ﬁnding in the studied
cohort was that only 10 cases had an increased number
of the so-called squiggle cells (>6/HPF), three of which
were later conﬁrmed to have OS. Most biopsies did not
include lamina propria and only eight biopsies
contained a small amount of superﬁcial lamina propria.
Therefore, the presence or absence of ﬁbrosis could not
be assessed.
The clinical management and follow-up are presented
in table 4.
One patient was lost from follow-up. The diagnosis of
EO was conﬁrmed in 13 of the 23 (56.5%) cases; 7 of the
23 (9%) patients improved with treatment for GORD
and were ascribed to the OS; 2 of the 23 (9%) cases later
developed eosinophilic gastroenteritis and in 1 of the 23
(4%) case, the upper gastrointestinal symptoms did not
recur and the patient was later diagnosed as having
irritable bowel syndrome. Four of the 13 patients with
EO showed no response to PPI and had a normal pH
study; 6 of the 13 patients with no response to PPI
treatment improved with diet management with or
without the addition of topical budesonide (no pH study
had been performed) and 3 of the 13 patients, although
with abnormal pH results who did not improve with PPI
treatment, responded to oral steroids and/or diet.
Our institution serves a population of 2 million,
250000 of whom are younger than 16 years of age.
20
During the 2-year study period, 1046 patients had upper
gastrointestinal endoscopies with oesophageal biopsy at
our hospital. The incidence of oesophageal eosinophilia
in this cohort was calculated to be 2.2%, while that of EO
(after further tests, treatment and 2- to 4-year follow-up)
was 1.2%. One hundred and ﬁfty-seven (15%) of all
patients referred for upper gastrointestinal endoscopy in
Table 2 Pre- and post-biopsy diagnosis and initial clinical management of the cohort
Case
Clinical diagnosis
(pre-biopsy)
PPI trial (pre- or
post-biopsy) pH study
Clinical diaxnosis
post-biopsy
1 EO Y (post) Normal EO
2 EO Y (post) Normal EO
3 GORD Y (pre) Normal EO
4 GORD Y (pre) ND EO + GORD (OS)
5 GORD Y (pre) Normal EO
6 ?GORD or
non-ulcer dyspepsia
Y (post) ND EO
7 ?GORD Y (pre) Abnormal reﬂux
index of 13%
EO + GORD (OS)
8 ?GORD Y (pre) Abnormal reﬂux
index of 8.8%
EO + GORD (OS)
9 GORD Y (pre) Abnormal reﬂux
index of 19.6%
EO + GORD (OS)
10 ?GORD Y (pre) Normal EO + GORD
11 ?EO Y (post) ND EO
12 ?GORD Y (post) Normal EO
13 ?GORD Y (pre) Abnormal reﬂux
index of 12.2%
EO + GORD (OS)
14 ?CMPA Y (post) Normal EO
15 Achalasia of
the cardia? EO
Y (pre) ND EO
16 Gastritis Y (pre) ND EO
17 ?CMPA Y (post) Abnormal reﬂux
index of 16.8%
EO + GORD (OS)
18 ?EO Y (post) Abnormal reﬂux
index of 10.7%
EO + GORD (OS)
19 Likely CMPA ND ND EO
20 Iron deﬁciency aneamia,
?coeliac disease
ND ND EO
21 ?EO Y (pre) ND EO
22 ?GORD Y (pre) 173 reﬂux
episodes/24 h
(normal is <75)
EO + GORD (OS)
23 ?GORD Y (pre) Normal EO
24 ?EO, ?GORD Y (pre) ND EO
CMPA, cow milk protein allergy; EO, eosinophilic oesophagitis; GORD, gastrooesophageal reﬂux disease; N, no; ND, not done; OS, overlap
syndrome; PPI, proton pump inhibitor; Y, yes; ?, suspected clinical diagnosis.
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(data not shown). Therefore, the incidence of oeso-
phageal eosinophilia among all cases with oesophagitis
(24 of the 157) was 15%, while that of EO (13 of the 157)
was 8.2%. We estimate that the incidence of oesophageal
eosinophilia in our region is 9/100000 children, while
that of EO is 4.5/100000 children.
DISCUSSION
The presence of mere ‘eosinophilia’ in the gastrointes-
tinal mucosa is seen in numerous conditions. The
differential diagnosis includes IgE-mediated food allergy,
eosinophilic gastroenteritis, allergic colitis, inﬂammatory
bowel disease, hypereosinophilic syndrome, drug reac-
tions, collagen vascular disease, parasitic infections,
myeloproliferative disorders and EO.
10 17
The concept of EO is more complex than the simple
presence of eosinophils in the mucosa. In EO, the
occurrence of >15 to 20 eosinophils/HPF is restricted to
the oesophagus, and these have a preferential local-
isation near the surface of the epithelium in a back-
ground of basal cell hyperplasia and papillary
elongation. The number of eosinophils/HPF varies
according to different investigators. While some require
$20 eosinophils/HPF,
8e10 others use $24/HPF
11 and
yet nowdas it is in our institutiond$15 eosinophils/
HPF are accepted as in keeping with EO.
10 21e24 Eosin-
ophil microabscesses with degranulation phenomena, if
present, are further supportive of this diagnosis.
25 26
Many studies also indicate that in EO, GORD needs to be
excluded by normal pH monitoring and failure to
respond to high-dose PPI therapy.
8e10
In addition to the presence of eosinophils, basal cell
hyperplasia and DIS have also been reported to be
a frequent ﬁnding in EO.
17 25 27e29 The mechanism
of DIS is through loss or rearrangement of inter-
cellular glycoconjugates that ‘seal’ the intercellular
spaces, impairing sodium transport and causing water
Figure 1 (A) Endoscopic appearance of eosinophilic oesophagitis (EO) showing ‘trachealisation’ of the oesophagus and white
speckles (*); (B) biopsy from the middle oesophagus depicting 53 eosinophils/high-power ﬁeld. These were located towards the
surface of the mucosa (H&E 340, case 2). (C) Dilatation of the intercellular spaces (curved arrow), papillary elongation and basal
cell hyperplasia were frequent changes present in biopsies with EO (H&E 340, case 4). (D) Microabscesses containing more than
four eosinophils present near the surface of the mucosa (arrow) (H&E 340, case 10).
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30 31 It is possible
that eosinophilic inﬁltration causes mucosa cell damage
and increased permeability that render the oesophageal
mucosa susceptible to injury by gastric acid.
25 The
presence of lamina propria ﬁbrosis has also been
described as a feature of EO and can be related to the
occurrence of oesophageal stenosis.
21 32
The symptoms of EO are often difﬁcult to distinguish
from those of GORD thus posing a management
dilemma.
22 These include vomiting, regurgitation,
nausea, epigastric pain, heartburn, food aversion,
dysphagia and failure to thrive,
81 11 73 33 4all of which
were present in our cases (see table 1). Interestingly, the
most common presenting features in our cohort were
symptoms related to allergy (11 of the 24). Dysphagia,
which was present in only ﬁve of our cases, has been
reported as the most common feature of EO in patients,
both adults and children.
15 16 27 34
We calculated the incidence of oesophageal eosino-
philia among all cases of oesophagitis in our region to be
15%, although the incidence of EO is only 8.2%. This
ﬁgure is higher than the 6.8% reported by Fox et al
34 and
lower than the incidence documented by Lim et al.
33 The
incidence of oesophageal eosinophilia in our region is
9/100000 children, while the incidence of EO is half of
this amount. This ﬁgure is less than the 2e4/10000
children cited by Noel et al
14 and Rothenberg.
17
However, Straumann and Beglinger
16 reported an
average annual incidence of 1.438 cases per 100000
population throughout a 16-year observation period
(range 0e6). This wide range of ﬁgures probably reﬂects
the different population studied, differences in the
diagnostic thresholds or under-recognition of the
condition.
As previously seen in both adults and children,
9 14 15
we have also noticed a marked increase in the number of
cases of EO during the last few years (data not shown).
As a matter of fact, a few years ago paediatric EO was not
offered as a diagnosis at all. It is likely that the rising
incidence of EO could be due to increased recognition
Table 3 Initial clinical diagnosis (pre-biopsy) and histological features present in the cohort group
Case
Clinical Dx
pre-biopsy
E/HPF
(biopsy site) DIS
Basal cell
hyperplasia
Cell
vacuolisation Squiggle cells
Papillary
elongation
1 EO 5 (P), 33 (D) + + + Not increased +
2 EO 55 (P, M, D)* +++ +++ +++ Not increased +++
3 GORD 16 (un) +++ +++ ++ Increased ++
4 GORD 50 (un) +++ +++ ++ Not increased +++
5 GORD 40 (D) No + No Not increased No
6 ?GORD or
non-ulcer dyspepsia
22 (un) +++ ++ ++ Increased No
7 ?GORD 46 (un) +++ +++ +++ Not increased +++
8 ?GORD 30 (P, D) +++ +++ +++ Increased +++
9 GORD 0 (P) 24 (D)* +++ + + Not increased +
10 ?GORD 40 (D)* +++ +++ +++ Increased +++
11 ?EO 30 (P), 50 (D) ++ ++ ++ Not increased ++
12 ?GORD 35 (D) ++ ++ ++ Not increased ++
13 ?GORD 30 (P), 20 (M),
20 (D)
++ ++ ++ Mild increase ++
14 ?CMPA 4 (P) 0 0 0 Not increased 0
35 (D) +++ +++ +++ Not increased +++
15 Achalasia
cardia, ?EO
25 (P), 34 (D) ++ ++ ++ Not increased,
increased
+++
16 Gastritis 40 (un) +++ +++ +++ Not increased ++
17 ?CMPA 24 (un)* ++ ++ ++ Not increased ++
18 ?EO 26 (P), 43 (D) +++ +++ +++ Increased,
not increased
+++
19 Failure to thrive 21 (un) + + + Not increased 0
20 Iron deﬁciency
aneamia, ?coeliac
disease
25 (un) + 0 0 Not increased 0
21 ?EO 15 (un) + +++ + Increased +++
22 ?GORD 16 (P), 0 + 0 Increased ++
57 (D) +++ +++ +++ Increased +++
23 ?GORD 45 (un) + + + Not increased 0
24 ?EO ?GORD 46 +++ ++ ++ Increased +
*Microabscesses; +, mild; ++, moderate; +++, marked.
CMPA, cow milk protein allergy; D, distal; DIS, dilatation of intercellular space; Dx, diagnosis; E/HPF, eosinophils/high-power ﬁeld (403); EO,
eosinophilic oesophagitis; GORD, gastrooesophageal reﬂux disease; M, middle; P, proximal; un, unknown; ?, suspected clinical diagnosis.
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Case
Pre-treatment clinical
diagnosis (after biopsy) Treatment and follow-up (2009e2011)
Final clinical
diagnosis
1 EO Initial histological response to anti-IL-5 for up to 6 months
but then rebound EO warranting treatment with 6 weeks
of exclusive elemental feed with good clinical and
histological response. Symptoms have now rebound and
currently on introduction of dietary protein. Feed aversive
behaviour. Atopy.
EO
2 EO Initial clinical and histological response to egg-, wheat-,
banana- and nut-free diet. However, with worsening asthma,
his symptoms have re-surfaced, i.e., vomiting and low
appetite with some clinical response to leucotriene
receptor antagonist.
EO
3 EO Exclusion diet. Gradual improvement of symptoms and at
discharged from care at 2 years.
EO
4 EO + GORD (OS) Clinical improvement in symptoms with long-term PPI and
domperidone at 2-year follow-up was gradually being weaned
off PPI at 2-year follow-up.
GORD (OS)
5 EO Short-term PPI and gradually weaned off by 1 year of age. GORD (OS)
6 EO Some clinical response to dairy-free diet but then went onto
develop feed aversive behaviour and slow transit constipation
on follow-up at 2 years. Parents not keen on re-assessment
scope as dietary restriction very difﬁcult due to behavioural
difﬁculties.
EO
7 EO + GORD (OS) Had a gastrostomy. With improvement in nutrition and weight
gain, signiﬁcant improvement in asthma and gastrointestinal
symptoms and discharged from care at 2-year follow-up.
EO
8 EO + GORD (OS) PPI treatment for 6 months with resolution of symptoms. GORD (OS)
9 EO +GORD (OS) Initial clinical response to 6-week elemental feed regime and
gradual reintroduction of proteins in diet over 3 months. Kept
on PPI for 1 year and weaned off by 2nd year. No
gastrointestinal or respiratory symptoms at 2-year follow-up.
GORD (OS)
10 EO + GORD (OS) Stayed on PPI with partial control of symptoms and care then
transferred to adult gastroenterologist.
GORD (OS)
11 EO Given a trial of PPI with no improvement in symptoms of
vomiting, feed aversion and eczema. Then found to have
multiple food allergies on RAST testing. At 6 months of age,
put on six protein-free diet (milk, soya, egg, nuts, ﬁsh and
wheat) with complete resolution of symptoms by 9 months.
On reintroduction was symptomatic with milk, soya, eggs and
wheat but asymptomatic with other nuts and ﬁsh. Discharged
from gastro follow-up at 14 months.
EO
12 EO EO identiﬁed at the time of gastrostomy insertion along with
signiﬁcant acid reﬂux. Trial of PPI had some improvement but
no resolution. Later Neocate and dairy/soya-free diet with both
clinical and histological resolution at 9 months post-diagnosis.
She then went into adoption and care was transferred.
GORD (OS)
13 EO + GORD (OS) Persistence of symptoms despite of topical steroids. At 2-year
follow-up, was commenced on oral steroids and had a clinical
response to his dysphagia.
EO
14 EO Subsequently developed eosinophilic gastroenteritis. Excellent
response to dairy-free diet on follow-up.
Eosinophilic
gastroenteritis
15 EO Initial poor response to topical budesonide. Subsequently
symptomatic improvement on six protein elimination diet.
EO
16 EO Partial response to PPI but had PEG inserted during the same
procedure. After 6-week trial of PPI, went onto Neocate
(elemental feed) for 6 weeks. At 18 months dairy and soya
reintroduced in diet with tolerance.
EO
17 EO + GORD (OS) Lost to follow-up.
Continued
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increasing number of endoscopy procedures performed
in patients with upper gastrointestinal tract symptoms.
Classically, EO shows a male-to-female ratio of
3:1.
13 15 23 27 Our cohort failed to show a male
predominance when EO and OS were analysed together
(11 males:9 females). However, this became apparent
when only cases of EO were analysed (9 males:4 females).
The endoscopic appearance of EO is puzzling.
Endoscopy is described as showing a ring-like oesoph-
agus (trachealisation), longitudinal linear furrows, fria-
bility or multiple small white papules suggestive of
Candida.
19 22 27 28 Interestingly, a study that addressed
the correlation between endoscopic and histological
features demonstrated a striking accumulation of
eosinophils in those biopsies taken from ‘white’ fungal-
looking areas.
11 In a paediatric series, white specks were
described in approximately 30% of the cases and have
been demonstrated to have a speciﬁcity of 95%
27 33
However, histologically severe EO can be associated with
normal-looking mucosa at endoscopy.
35 Indeed, nine of
our cases had normal endoscopy.
Eosinophils are specialised cells that contain granule
proteins, cytokines, platelet-activating factors and
leucotrienes. Their main role is traditionally thought to
be combating parasitic infections, although they can be
stimulated by a variety of other triggers such as tissue
injury, allergens and viruses.
17 Their cytoplasmic gran-
ules contain a major basic protein, eosinophil cationic
protein, peroxidase and a neurotoxin that has been
linked to the presence of dysphagia in many patients.
36
Some authors postulate that EO is an interleukin
5-driven inﬂammatory disorder of the oesophagus in
which the aetiology could be linked to a combination of
allergic and immunologic responses.
11 12 Allergic disor-
ders are noted to be more common in patients with EO
than in those with GORD, and the majority of patients
show food and aeroallergen hypersensitivity identiﬁed by
skin prick tests, food-speciﬁc radioallergosorbent testing
(RAST) or both.
10 12 17 37e39 Eleven (46%) of our cases
of oesophageal eosinophilia and 5 of the 13 (38.5%)
with EO had an associated allergic condition including
asthma, eczema and cow milk protein allergy. One
additional patient, although not showing clinical or
histological features of coeliac disease, improved with
a gluten-free diet. Coeliac disease and EO have been
reported in six patients.
40 However, the eosinophilic
inﬁltration in the oesophagus did not improve with
gluten-free diet in these cases.
40 The relevance of these
ﬁndings suggests the need to refer patients with EO for
food allergy evaluation, a practice more commonly seen
in paediatric than adult gastroenterology practice.
41
Eotaxins are a group of chemokines that are relatively
speciﬁc for eosinophils and have a key role in the
modulation of eosinophil accumulation in the gastroin-
testinal tract.
17 All eotaxins act on a selective trans-
membrane eotaxin CCR3 receptor primarily expressed
on eosinophils. The same eotaxin CCR3 receptor is also
expressed in gastrointestinal mast cells. Using genetic
microarray expression proﬁle analysis, Blanchard et al
18
demonstrated an approximately 50-fold overexpression
of the gene of eotaxin-3 in the oesophageal mucosa of
Table 4 Continued
Case
Pre-treatment clinical
diagnosis (after biopsy) Treatment and follow-up (2009e2011)
Final clinical
diagnosis
18 EO + GORD (OS) Partial response to PPI alone and then subsequently put on
dairy-free diet with clinical improvement in symptoms.
Gradually weaned off PPI and at 2 years back onto dairy with
no recurrence of symptoms.
GORD (OS)
19 EO Subsequently developed eosinophilic gastroenteritis. Good
response to dairy-, soya- and wheat-free diet.
Eosinophilic
gastroenteritis
20 EO Persistently positive coeliac serology. Re-scoped after 18 months
on a gluten-containing diet with no evidence of coeliac disease
but persistence of EO. Symptoms of pain did not improve on
dairy- or wheat-free diet and was put on topical budesonide with
some positive response.
EO
21 EO No upper gastrointestinal I symptoms after histological diagnosis.
Only had intermittent diarrhoea, which was subsequently
diagnosed as having irritable bowel syndrome and responded well
to Mebeverine and Loperamide.
Irritable bowel
syndrome
22 EO + GORD (OS) Initial lack of response to PPI and anti-histamine but at 2-year
follow-up responded to dairy-free diet.
EO
23 EO Improvement on dairy- and soya-free diet. Symptoms appear to be
re-surfacing on reintroduction of soya. Due to a repeat endoscopy.
EO
24 EO No improvement in symptoms on dairy-free diet and some response
to topical budesonide gel. Lost to follow-up.
EO
EO, eosinophilic oesophagitis; GORD, gastrooesophageal reﬂux disease; IL-5, interleukin 5; OS, overlap syndrome; PPI, proton pump inhibitor;
RAST test, radioallergosorbent test.
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Oesophageal eosinophilia in childrenpatients with EO compared with controls, suggesting
a role of eotaxin in the pathogenesis of EO. The level of
eotaxin-3 mRNA and protein strongly correlated with the
number of eosinophils in the oesophageal mucosa. They
also showed that mast cell gene expression is highly
increased in EO. This correlates with the description of
increased number of mast cells and mast cell degranula-
tion in oesophageal biopsies of patients with EO.
17 18 24 25
pH studies are generally considered useful to distin-
guish patients with EO from those with GORD.
10 12 33
Although our results are limited due to the retrospective
nature of the study and the small number of cases, our
ﬁndingsdin agreement with those obtained by other
authors
25 42 43dsuggest that there is overlap in the
clinical and histological features of EO and GORD. Both
ends of the spectrum are not so difﬁcult to recognise but
sometimes differentiating between these two conditions
can be challenging.
24 Moreover, the possibility of an
‘overlap’ group showing features of both conditions has
also been demonstrated in previous studies.
25 42 43 The
identiﬁcation of those patients with OS has therapeutic
implications, as the addition of acid blockade and
prokinetic agents can aid in healing by reducing expo-
sure to acid which adds a further insult to the mucosa.
Thirty per cent (7 of the 23) of our cases with oeso-
phageal eosinophilia had evidence of GORD that
improved with PPI treatment (OS). This ﬁgure is
approximately three-quarters of the 40% reported by
Remedios et al
42 in adults with EO. A recent report
demonstrated resolution of oesophageal eosinophilia in
three children with clinical symptoms as well as endo-
scopic features of EO following a course of PPI therapy,
43
indicating that a large number of eosinophils can be seen
in patients with GORD. The underlying proposed mech-
anism is that either EO causes a dysfunction of the lower
oesophageal sphincter or an allergy type reaction of the
oesophageal mucosa to reﬂux contents.
16 28 42 This would
explain why as many as 94% of children with EO exhibit
reﬂux symptoms refractory to PPI therapy.
43 In line with
this proposal, 3 of the 13 cases that were clinically cate-
gorised as EO after 2-year follow-up demonstrated
abnormal pH results but their symptoms did not improve
with PPI treatment, although disappeared or markedly
improved with oral steroids and/or diet.
Rothenberg
17 indicated that the presence of 7 to 20 to
24 eosinophils/HPF likely represents a combination of
GORD and food allergy, while >20 to 24 eosinophils/
HPF is characteristic of EO. In our study, the number of
intraepithelial eosinophils in the ‘overlap’ group was
between 16 and 57/HPF. Results from a recent histo-
morphological and immunohistological investigation
performed in adult patients with EO concluded that the
differential diagnosis of EO and GORD cannot be based
on counts of eosinophils alone and that the presence
and intensity of secondary changes such as basal cell
hyperplasia, DIS and vacuolisation of keratinocytes
would be helpful to better delineate these two condi-
tions.
25 If EO is suspected, endoscopy with biopsy and
histology is critical to achieve the correct clinicopatho-
logic diagnosis.
In summary, we have presented the clinical, endo-
scopic, histological and epidemiological features of
oesophageal eosinophilia in our area. A signiﬁcant
proportion of patients had either EO or EO associated
with GORD (OS). Further studies need to be done in
order to delineate the interaction between genetic
factors, allergens and eosinophils. This would help to
plan interventionist measures that could remedy the
perceived worldwide increasing incidence of EO. The
fact that after 2e4 years of treatment and follow-up,
approximately two of the three patients were diagnosed
as having classical EO, and one of the three as the so-
called OS (GORD + OE) highlights the importance of
keeping longitudinal data on these patients. As a conse-
quence of the study, we have now introduced a register of
patients with features of EO, aiming to gather long-term
follow-up data, which could assist in the identiﬁcation of
further histological and/or clinical characteristics that
would allow better management of the disease.
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